Clinical Transparency (dept. 2834)
Novo Nordisk A/S · Novo Nordisk A/S'
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Clinical Transparency (dept. 2834) as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Showing 200 of 328. Open this list on ClinicalTrials.gov
- Ph3NCT07919405 · A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNovo Nordisk A/S · not yet recruiting · Hypertension, Obesity · study director
- Ph4NCT07900438 · A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaNovo Nordisk A/S · recruiting · Cardiovascular Risk, Chronic Kidney Disease · study director
- Ph1NCT07896109 · A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 DiabetesNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2
- N/ANCT07881770 · Semaglutide Health Outcomes and Patient Adherence in AustraliaNovo Nordisk A/S · not yet recruiting · Overweight, Obesity · study director
- Ph1NCT07868354 · A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationNovo Nordisk A/S · recruiting · Overweight, Obesity, Type 2 Diabetes · study director
- Ph3NCT07861100 · A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNovo Nordisk A/S · not yet recruiting · Cardiovascular Risk, Obesity · study director
- Ph1NCT07855133 · A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationNovo Nordisk A/S · recruiting · Overweight, Obesity, Type 2 Diabetes · study director
- N/ANCT07850765 · Real-World Patient and Physician Experience With Semaglutide Across Six Emerging MarketsNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph1NCT07845578 · A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightNovo Nordisk A/S · not yet recruiting · Obesity, Overweight · study director
- Ph1NCT07829406 · A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy PeopleNovo Nordisk A/S · recruiting · Healthy Volunteers · study director
- Ph3NCT07830732 · A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia ANovo Nordisk A/S · recruiting · Haemophilia A · study director
- Ph3NCT07822061 · AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose WeightNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph3NCT07817251 · Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2 · study director
- Ph1NCT07815067 · A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07808788 · A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney FunctionNovo Nordisk A/S · not yet recruiting · Chronic Kidney Disease
- Ph1NCT07797855 · A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy PeopleNovo Nordisk A/S · recruiting · Healthy Volunteers, Cardiometabolic Diseases · study director
- N/ANCT07781371 · A Retrospective Real-World Cohort StudyNovo Nordisk A/S · active not recruiting · Obesity, Type 2 Diabetes (T2D), Prediabetes · study director
- Ph1NCT07769489 · Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNovo Nordisk A/S · recruiting · Healthy Participants
- Ph3NCT07770841 · Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07767175 · A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07757087 · A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or PlaceboNovo Nordisk A/S · recruiting · Overweight, Obesity
- Ph3NCT07745504 · A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- N/ANCT07739901 · Korean Real-world Study on MASLD/MASH Outcomes.Novo Nordisk A/S · active not recruiting · MASLD/MASH · study director
- Ph3NCT07720271 · AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- N/ANCT07713901 · Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaNovo Nordisk A/S · enrolling by invitation · Medullary Thyroid Carcinoma · study director
- Ph1NCT07710729 · A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become PregnantNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07710768 · A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body WeightNovo Nordisk A/S · recruiting · Obesity, Overweight · study director
- Ph1NCT07693868 · A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With ObesityNovo Nordisk A/S · recruiting · Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)
- N/ANCT07682363 · Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese PhysiciansNovo Nordisk A/S · recruiting · Liver Disease · study director
- N/ANCT07673822 · Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based StudyNovo Nordisk A/S · enrolling by invitation · Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease · study director
- Ph2NCT07668388 · A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2
- Ph3NCT07668414 · A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph3NCT07668401 · AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNovo Nordisk A/S · not yet recruiting · Obesity, Overweight · study director
- N/ANCT07658417 · Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecNovo Nordisk A/S · enrolling by invitation · Diabetes Mellitus, Type 2 · study director
- Ph1NCT07656454 · A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy ParticipantsNovo Nordisk A/S · recruiting · Healthy Volunteers, Heart Failure · study director
- N/ANCT07653139 · Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNovo Nordisk A/S · enrolling by invitation · Haemophilia A · study director
- Ph2NCT07639021 · A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNovo Nordisk A/S · active not recruiting · Obesity · study director
- N/ANCT07627074 · Weight Loss in Adults Using Semaglutide (Real-world Study)Novo Nordisk A/S · completed · Overweight, Obesity · study director
- N/ANCT07607600 · Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked HypophosphatemiaNovo Nordisk A/S · withdrawn · X-linked Hypophosphatemia (XLH)
- Ph1NCT07607587 · Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNovo Nordisk A/S · recruiting · Obesity, Overweight · study director
- Ph1NCT07605052 · A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph1NCT07597018 · A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNovo Nordisk A/S · recruiting · Obesity, Overweight · study director
- Ph1NCT07587710 · A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver FunctionNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07578584 · A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or ObesityNovo Nordisk A/S · recruiting · Type 1 Diabetes (T1D), Overweight, Obesity
- Ph3NCT07571109 · AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNovo Nordisk A/S · recruiting · Obesity, Overweight, Obstructive Sleep Apnoea
- Ph3NCT07571005 · AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNovo Nordisk A/S · recruiting · Obesity, Overweight, Obstructive Sleep Apnoea
- Ph1NCT07570992 · A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DMNovo Nordisk A/S · recruiting · Healthy Volunteers, Diabetes Mellitus, Type 2
- Ph1NCT07566390 · A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNovo Nordisk A/S · recruiting · Obesity, Overweight · study director
- Ph3NCT07567001 · A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNovo Nordisk A/S · recruiting · Obesity, Heart Failure · study director
- Ph3NCT07564414 · A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNovo Nordisk A/S · recruiting · Obesity, Type 2 Diabetes · study director
- Ph1NCT07557953 · A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07535307 · Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesNovo Nordisk A/S · recruiting · Diabetes Mellitus · study director
- Ph3NCT07533175 · AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNovo Nordisk A/S · active not recruiting · Diabetes Mellitus, Overweight, Obesity · study director
- N/ANCT07532863 · A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) ParticipantsNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2
- Ph1NCT07527195 · Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)Novo Nordisk A/S · recruiting · Obesity
- Ph1NCT07525791 · A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body WeightNovo Nordisk A/S · active not recruiting · Overweight, Obesity · study director
- Ph3NCT07509307 · AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNovo Nordisk A/S · recruiting · Obesity, Overweight, Osteoarthritis, Knee · study director
- Ph1NCT07508020 · A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With ObesityNovo Nordisk A/S · recruiting · Obesity · study director
- Ph3NCT07503210 · AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNovo Nordisk A/S · active not recruiting · Obesity · study director
- Ph3NCT07481630 · A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNovo Nordisk A/S · recruiting · Obesity, Knee Osteoarthritis (OA) · study director
- N/ANCT07456774 · A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in ChinaNovo Nordisk A/S · enrolling by invitation · Type 2 Diabetes
- Ph1NCT07448623 · A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.Novo Nordisk A/S · recruiting · Transthyretin Amyloid Cardiomyopathy
- Ph1NCT07437079 · A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph2NCT07415954 · A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2 · study director
- Ph1NCT07411560 · A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNovo Nordisk A/S · recruiting · Overweight, Obese · study director
- Ph3NCT07400107 · AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNovo Nordisk A/S · active not recruiting · Obesity, Overweight, Diabetes Mellitus, Type 2 · study director
- Ph2NCT07395687 · A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph3NCT07357766 · A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNovo Nordisk A/S · withdrawn · Overweight, Obesity
- Ph2NCT07357740 · A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNovo Nordisk A/S · withdrawn · Diabetes Mellitus, Type 2
- N/ANCT07358052 · Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE)Novo Nordisk A/S · completed · Obesity, Overweight
- Ph3NCT07339423 · AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNovo Nordisk A/S · recruiting · Obesity · study director
- Ph1NCT07305805 · A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 1 · study director
- Ph3NCT07301034 · A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart AttackNovo Nordisk A/S · recruiting · Myocardial Infarction · study director
- Ph3NCT07282613 · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2
- N/ANCT07280221 · WEgovy Real World Assessment of Weight Loss in KoreaNovo Nordisk A/S · enrolling by invitation · Obesity
- Ph3
- Ph1NCT07270731 · A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 DiabetesNovo Nordisk A/S · recruiting · Healthy Volunteer, Type 2 Diabetes
- Ph3NCT07253285 · A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNovo Nordisk A/S · recruiting · Overweight, Obesity · study director
- Ph1NCT07238816 · A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy PeopleNovo Nordisk A/S · completed · Haemophilia A · study director
- Ph1
- Ph3NCT07220642 · Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNovo Nordisk A/S · active not recruiting · Obesity, Overweight · study director
- Ph1NCT07220564 · A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANovo Nordisk A/S · recruiting · Haemophilia A · study director
- Ph3NCT07220759 · Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNovo Nordisk A/S · active not recruiting · Overweight, Obesity, Type 2 Diabetes · study director
- Ph1NCT07218627 · A Research Study on the Effects of NNC0537-1482 in Participants With Heart FailureNovo Nordisk A/S · recruiting · Heart Failure · study director
- Ph1NCT07214870 · A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver FatNovo Nordisk A/S · active not recruiting · Fatty Liver Disease · study director
- Ph3NCT07207811 · CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNovo Nordisk A/S · recruiting · Transthyretin Amyloid Cardiomyopathy (ATTR CM) · study director
- N/ANCT07201831 · A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk PopulationNovo Nordisk A/S · completed · Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Ph2NCT07184632 · A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNovo Nordisk A/S · active not recruiting · Overweight, Obesity · study director
- Ph1NCT07184086 · A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNovo Nordisk A/S · active not recruiting · Obesity · study director
- N/ANCT07163260 · Defeat Rare Disease in Asia and Pacific (APAC) DRDA - HaemophiliaNovo Nordisk A/S · enrolling by invitation · Haemophilia · study director
- N/ANCT07160829 · Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure ManagementNovo Nordisk A/S · completed · Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease
- N/ANCT07160816 · A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNovo Nordisk A/S · active not recruiting · Diabetes Mellitus, Type 1 · study director
- Ph4NCT07157423 · A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaNovo Nordisk A/S · recruiting · Severe Postpartum Haemorrhage · study director
- N/ANCT07154238 · Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.Novo Nordisk A/S · enrolling by invitation · Obesity · study director
- Ph1NCT07153172 · Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108Novo Nordisk A/S · recruiting · Obesity · study director
- N/ANCT07141914 · A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real WorldNovo Nordisk A/S · completed · Overweight, Obesity, Heart Failure (HF)
- N/ANCT07121114 · CAPTIVATE India - A Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals With Type 2 Diabetes Mellitus (T2DM) in IndiaNovo Nordisk A/S · completed · Type 2 Diabetes Mellitus · study director
- Ph1NCT07121153 · A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.Novo Nordisk A/S · completed · Overweight, Obesity
- Ph4NCT07112339 · A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 2 · study director
- Ph1NCT07101783 · A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or ObesityNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph1NCT07087795 · A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesNovo Nordisk A/S · active not recruiting · Diabetes Mellitus, Type 1 · study director
- N/ANCT07081178 · A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).Novo Nordisk A/S · terminated · Obesity · study director
- Ph3NCT07076199 · A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNovo Nordisk A/S · active not recruiting · Diabetes Mellitus, Type 1 · study director
- Ph1NCT07068295 · A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin PumpNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- N/ANCT07055607 · A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeNovo Nordisk A/S · enrolling by invitation · Obesity · study director
- N/ANCT07052292 · User Experience With DuraTouch® in Patients With Type 1 or Type 2 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · study director
- Ph1NCT07029568 · A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy PeopleNovo Nordisk A/S · completed · Healthy Volunteers, Chronic Kidney Disease · study director
- Ph1NCT07023029 · A Study on the Effect of Etavopivat on Heart Rhythm in Healthy ParticipantsNovo Nordisk A/S · completed · Healthy Volunteers, Sickle Cell Disease, Thalassemia · study director
- N/ANCT07018544 · A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in KoreaNovo Nordisk A/S · enrolling by invitation · Obesity and Overweight
- Ph3NCT07011667 · A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNovo Nordisk A/S · active not recruiting · Obesity · study director
- Ph1NCT07010432 · The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNovo Nordisk A/S · recruiting · Obesity · study director
- Ph1NCT07004322 · A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body WeightNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2, Obesity · study director
- Ph2NCT06979362 · A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyNovo Nordisk A/S · recruiting · Heart Failure · study director
- Ph2NCT06979375 · A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyNovo Nordisk A/S · recruiting · Heart Failure · study director
- Ph1NCT06891365 · Multiple Dose Study for a New Medication to Potentially Treat Liver DiseasesNovo Nordisk A/S · recruiting · Healthy Volunteers, Hepatic Steatosis · study director
- N/ANCT06874751 · Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real WorldNovo Nordisk A/S · completed · Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD) · study director
- Ph1NCT06859073 · A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic HyperuricemiaNovo Nordisk A/S · active not recruiting · Healthy Volunteers, Hyperuricemia · study director
- N/ANCT06855563 · Cities for Better Health Childhood Obesity Prevention InitiativeNovo Nordisk A/S · enrolling by invitation · Obesity · study director
- N/ANCT06843473 · Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and VietnamNovo Nordisk A/S · completed · Obesity, Obesity-related Complications · study director
- N/ANCT06831734 · Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With AlhemoNovo Nordisk A/S · enrolling by invitation · Haemophilia A, Haemophilia B · study director
- Ph1NCT06820476 · A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral DosingNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph1NCT06813924 · A Research Study of the Effect of Etavopivat on Other Drugs in Healthy ParticipantsNovo Nordisk A/S · completed · Healthy Volunteers Sickle Cell Disease, Thalassemia · study director
- Ph1NCT06809621 · A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin PumpNovo Nordisk A/S · completed · Diabetes Mellitus, Type 1 · study director
- N/ANCT06807190 · General Use-results Surveillance With Awiqli in Patients With Diabetes MellitusNovo Nordisk A/S · recruiting · Diabetes Mellitus, Type 1 · study director
- N/ANCT06805539 · A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management ProgramNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph2NCT06797869 · A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy · study director
- Ph3NCT06780449 · A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNovo Nordisk A/S · active not recruiting · Obesity · study director
- N/ANCT06769646 · SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world DataNovo Nordisk A/S · completed · Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD) · study director
- N/ANCT06741111 · A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up DatabaseNovo Nordisk A/S · completed · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH) · study director
- Ph1NCT06737536 · A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or ObesityNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph1NCT06718998 · A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or ObesityNovo Nordisk A/S · completed · Obesity · study director
- Ph1NCT06719011 · A Study on How NNC0174-1213 Works in People With Overweight or Obesity.Novo Nordisk A/S · completed · Obesity, Overweight · study director
- Ph2NCT06717698 · A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNovo Nordisk A/S · recruiting · Chronic Kidney Disease · study director
- Ph1NCT06716307 · A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNovo Nordisk A/S · completed · Obesity · study director
- N/ANCT06709040 · A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical ParametersNovo Nordisk A/S · enrolling by invitation · Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2 · study director
- Ph1NCT06685185 · A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 1 · study director
- N/ANCT06655493 · Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney DiseaseNovo Nordisk A/S · completed · Systemic Inflammation (hsCRP) · study director
- Ph1NCT06649630 · A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy MenNovo Nordisk A/S · completed · Haemophilia A · study director
- Ph1NCT06642571 · A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the MedicineNovo Nordisk A/S · completed · Obesity · study director
- Ph1NCT06642584 · A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IVNovo Nordisk A/S · completed · Healthy Volunteers Type 2 Diabetes · study director
- Ph1NCT06625307 · A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the SkinNovo Nordisk A/S · completed · Healthy Volunteers, Heart Failure · study director
- Ph3NCT06612268 · A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseaseNovo Nordisk A/S · recruiting · Sickle Cell Disease · study director
- Ph3NCT06609226 · A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaNovo Nordisk A/S · recruiting · Sickle Cell Disease, Thalassemia · study director
- N/ANCT06592950 · Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting InsulinNovo Nordisk A/S · completed · Type-2 Diabetes Mellitus (T2DM)
- N/ANCT06589791 · A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and NephrologistsNovo Nordisk A/S · completed · Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Ph1NCT06588504 · Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsNovo Nordisk A/S · completed · Diabetes Mellitus, Type 1 · study director
- Ph1NCT06581627 · A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese ParticipantsNovo Nordisk A/S · completed · Healthy Volunteers, Sickle Cell Disease, Thalassemia · study director
- Ph1NCT06577766 · A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or ObesityNovo Nordisk A/S · active not recruiting · Obesity, Overweight · study director
- N/ANCT06574984 · Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A PatientsNovo Nordisk A/S · completed · Congenital Bleeding Disorder, Haemophilia A · study director
- Ph4NCT06571383 · STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight LossNovo Nordisk A/S · active not recruiting · Obesity · study director
- Ph1NCT06567041 · A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2, Obesity · study director
- Ph1NCT06559527 · A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2, Obesity, Overweight · study director
- Ph2NCT06542874 · A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNovo Nordisk A/S · completed · Type 2 Diabetes (T2D) · study director
- Ph1NCT06542536 · A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian MenNovo Nordisk A/S · completed · Obesity · study director
- Ph3NCT06534411 · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- N/ANCT06517784 · Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 DiabetesNovo Nordisk A/S · completed · Type 2 Diabetes
- Ph1NCT06513104 · A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After MenopauseNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- N/ANCT06507475 · Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph1NCT06504368 · Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid TumorsDicerna Pharmaceuticals, Inc., a Novo Nordisk company · recruiting · Solid Tumors, Adult · study director
- N/ANCT06478550 · A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This TreatmentNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph1NCT06478563 · A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or ObesityNovo Nordisk A/S · completed · Obesity, Overweight · study director
- Ph1NCT06461039 · A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become PregnantNovo Nordisk A/S · completed · Obesity · study director
- Ph1NCT06433661 · A Research Study of the Effect of Food on Etavopivat in Healthy ParticipantsNovo Nordisk A/S · completed · Healthy Volunteers Sickle Cell Disease, Thalassemia · study director
- Ph2NCT06409130 · Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNovo Nordisk A/S · completed · Alcohol-related Liver Disease · study director
- Ph1NCT06403761 · Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph3NCT06388187 · A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNovo Nordisk A/S · completed · Obesity · study director
- Ph1NCT06370819 · A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney FunctionNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- N/ANCT06351748 · Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)Novo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph3NCT06340854 · A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesNovo Nordisk A/S · completed · Diabetes, Type 2 · study director
- Ph1NCT06336005 · A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy PeopleNovo Nordisk A/S · completed · Healthy Volunteers, Cardiometabolic Diseases · study director
- Ph1NCT06336018 · A Research Study on Etavopivat in Participants With and Without Liver DiseaseNovo Nordisk A/S · completed · Liver Diseases · study director
- Ph2NCT06326047 · A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph2NCT06326060 · A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightNovo Nordisk A/S · completed · Obesity · study director
- Ph3NCT06323161 · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNovo Nordisk A/S · completed · Type 2 Diabetes · study director
- Ph3NCT06323174 · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNovo Nordisk A/S · completed · Type 2 Diabetes · study director
- N/ANCT06322641 · A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among NephrologistsNovo Nordisk A/S · completed · Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
- Ph1NCT06289504 · A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNovo Nordisk A/S · completed · Obesity · study director
- Ph1NCT06291285 · A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy PeopleNovo Nordisk A/S · completed · Healthy Volunteers · study director
- Ph1NCT06288412 · A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged FastingNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph1NCT06284798 · A Research Study of a New Medicine (NNC0650-0013) in Healthy MenNovo Nordisk A/S · completed · Healthy Participants · study director
- N/ANCT06285071 · Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With InhibitorsNovo Nordisk A/S · enrolling by invitation · Haemophilia A, Haemophilia B
- N/ANCT06283667 · Special Use - Results Surveillance on Long-term Use With Wegovy®Novo Nordisk A/S · active not recruiting · Obesity · study director
- N/ANCT06283641 · Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.Novo Nordisk A/S · completed · Obesity · study director
- N/ANCT06269120 · SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in HungaryNovo Nordisk A/S · completed · Type 2 Diabetes · study director
- Ph3NCT06269107 · A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)Novo Nordisk A/S · completed · Type 2 Diabetes · study director
- N/ANCT06260696 · Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by GenderNovo Nordisk A/S · completed · Overweight, Obesity · study director
- Ph2NCT06260709 · A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin AmyloidosisNovo Nordisk A/S · active not recruiting · Transthyretin Amyloid Cardiomyopathy (ATTR CM) · study director
- Ph3NCT06221969 · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNovo Nordisk A/S · completed · Type 2 Diabetes · study director
- Ph1NCT06207877 · A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNovo Nordisk A/S · completed · Obesity · study director
- Ph2NCT06198712 · A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseForma Therapeutics, Inc. · recruiting · Sickle Cell Disease · study director
- Ph3NCT06200207 · A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNovo Nordisk A/S · active not recruiting · Heart Failure, Systemic Inflammation
- Ph1NCT06188026 · A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.Novo Nordisk A/S · completed · Healthy Volunteers (Non-alcoholic Steatohepatitis) · study director
- N/ANCT06153537 · A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar LevelNovo Nordisk A/S · completed · Diabetes Mellitus, Type 2 · study director
- Ph1NCT06133270 · A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.Novo Nordisk A/S · completed · Healthy Volunteers - Liver Diseases · study director
- Ph2NCT06131372 · A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNovo Nordisk A/S · completed · Chronic Kidney Disease, Type 2 Diabetes, Obesity · study director
- Ph3NCT06131437 · A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNovo Nordisk A/S · completed · Obesity · study director
- N/ANCT06122961 · Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)Novo Nordisk A/S · completed · Cardiovascular Risk, Heart Failure, Chronic Kidney Disease · study director
- Ph3NCT06118281 · ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNovo Nordisk A/S · active not recruiting · Cardiovascular Risk, Acute Myocardial Infarction (AMI)
- N/ANCT06113341 · A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 DiabetesNovo Nordisk A/S · withdrawn · Diabetes Mellitus, Type 2 · study director
- N/ANCT06109935 · Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not ClosedNovo Nordisk A/S · enrolling by invitation · Growth Hormone Deficiency in Children
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.